Femoston 1/5 as a preparation continuous combined hormonotherapy in pre- and postmenopausal patients

Abstract

The paper presents the results of a study of a low-dose drug for continuous HRT - Femoston 1/5. The drug quite effectively eliminates (reduces) psychoemotional and vegetative-vascular symptoms of peri- and postmenopause, eases the course of hypertension, does not affect body weight gain, actually does not cause breakthrough bleeding, growth of myomatous nodes, does not affect the size of the uterus and the thickness of the endometrium (within a year reception). Taking the drug is accompanied by positive dynamics of the level of glycemia, high and low density lipoproteins, the degree of aggregation and intravascular activation of platelets, which improves the state of peripheral blood flow.

The presented data allow us to recommend Femoston 1/5 as a means of HRT for postmenopausal and perimenopausal patients with concomitant uterine myoma and endometriosis.

Keywords

hormone replacement therapy / perimenopause / postmenopause / femoston / endometriosis

References

[1] Репина М. А Подходы к профилактике сосудистых нарушений у женщин в возрасте пери и постменопаузы. Проблемы репрод. — 1996. — № 3. - С. 55-59.

[2] Шитикова А. С., Каргин В. Д., Белязо О. Е. и др. Морфологическая оценка повышенной внутрисосудистой активации тромбоцитов. Методич. Реком., 1996, СПб.

[3] Bush Т. L. Evidence for primary and secondary of coronary artery disease in women taking oestrogen replacement therapy. Eur. Heart J., 1996. — Vol. 17, suppl. D. — P. 9-14.

[4] Cardozo L. The role of oestrogens in urogynaecology: Low-dose therapy. European Consensus Development Conference «Menopause», 1996. — P. 59—65.

[5] Christiansen C. Nilas L., Riis B. et al Uncoupling of bone formation and resorption by combined oestrogen and progestagen therapy in postmenopausal osteoporosis. Lancet, 1985. - N 2. - P. 800-801.

[6] Colditz G. A.; Hankinson S. E.; Hunter D. J. et al The use of estrogens and progestins and the risk of breast cancer in post-menopausal women. N. Engl. J. Med., 1995. - Vol. 332. - P. 1589-1593.

[7] Devor M., Barrett-Connor E., Renvall M. et al Estrogen replacement therapy and the risk of venous thrombosis. Am. J. Med., 1992. - Vol. 92. - P. 275-282.

[8] Ewertz M., Schou G., Boice J. D. The joint effect of risk factors on endometrial cancer. Eur. J. Cancer. Clin. Oncol.,

[9] - Vol. 24. - P. 189-194.

[10] Henderson В. E., Paganini-Hill A., Ross R. K. Decreased mortality in users of estrogen replacement therapy. Arh. Int. Med., 1991. - Vol. 151. - N 1. - P. 75-78.

[11] Henderson V. W. Hormone therapy and the brain, 1999, New York

[12] Luscher T. E., Tanner F. C., Noll G. Lipids and endothelial function: effects of lipid-lowering and other therapeutic interventions. Curr. Opin. Lipidol. 1996. — Vol. 7. - P. 234-240.

[13] Lufkin E. C., Wahner H. W., O'Fallon W. M. et al Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern. Med., 1992. — Vol. 117. - N 1. - P. 1-9.

[14] Metka M. How important are sexual steroids in extragenital organs? European Consensus Development Conference «Menopause», 1996. — P. 45—49.

[15] Ohkura T., Jsse K., Akazawa K. et al Low-dose estrogen replacement therapy for Alzheimer disease in women. Menopause, 1994. - N 1. - P. 125-130.

RIGHTS & PERMISSIONS

Eсо-Vector